Description

The utility of the levels of amyloid beta (Aβ) peptide and tau in blood for diagnosis, drug development, and assessment of clinical trials for Alzheimer’s disease (AD) has not been

The utility of the levels of amyloid beta (Aβ) peptide and tau in blood for diagnosis, drug development, and assessment of clinical trials for Alzheimer’s disease (AD) has not been established. The lack of availability of ultra-sensitive assays is one critical issue that has impeded progress. The levels of Aβ species and tau in plasma and serum are much lower than levels in cerebrospinal fluid. Furthermore, plasma or serum contain high levels of assay-interfering factors, resulting in difficulties in the commonly used singulex or multiplex ELISA platforms.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2017-07-21
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    • Digital object identifier: 10.1007/s40120-017-0074-8
    • Identifier Type
      International standard serial number
      Identifier Value
      2193-8253
    • Identifier Type
      International standard serial number
      Identifier Value
      2193-6536
    Note

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Lue, L., Guerra, A., & Walker, D. G. (2017). Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies. Neurology and Therapy, 6(S1), 25-36. doi:10.1007/s40120-017-0074-8

    Machine-readable links